Academic Journals Database
Disseminating quality controlled scientific knowledge

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer

Author(s): Daiki Ogawara | Minoru Fukuda | Yoichi Nakamura | et al

Journal: Cancer Management and Research
ISSN 1179-1322

Volume: 2010;
Issue: default;
Start page: 191;
Date: 2010;
Original page

Daiki Ogawara1, Minoru Fukuda2, Yoichi Nakamura3, Shigeru Kohno31Department of Medicine, Sasebo Central Hospital, 2Department of Medicine, Nagasaki Municipal Hospital, 3Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, JapanAbstract: Long-term survival is quite uncommon in refractory small cell lung cancer (SCLC) patients, with less than 25% of patients with limited-stage disease and 1%–2% of patients with extensive-stage disease remaining alive at five years. Recent clinical studies have demonstrated the promising efficacy of amrubicin for patients with relapsed SCLC. This review presents the results of clinical studies showing the efficacy and safety of amrubicin for the treatment of relapsed SCLC. Amrubicin is a synthetic anthracycline agent with a similar structure to doxorubicin, in which the hydroxyl group at position 9 in amrubicin is replaced by an amino group to enhance efficacy. It is converted to an active metabolite, amrubicinol, which is 5–54 times more active than amrubicin. Amrubicin and amrubicinol are inhibitors of DNA topoisomerase II, exerting their cytotoxic effects by stabilizing a topoisomerase II-mediated cleavable complex. The toxicity of amrubicin is similar to that of doxorubicin, although amrubicin shows almost no cardiotoxicity. In the relevant trials, amrubicin was administered intravenously at a dose of 35–40 mg/m2 on days 1–3 every three weeks. The response rate was 34%–52% and median survival times were 8.1–12.0 months. Common hematologic toxicities included neutropenia, leucopenia, anemia, thrombocytopenia, and febrile neutropenia. Nonhematologic adverse events included Grade 3–4 anorexia, asthenia, hyponatremia, and nausea. The results of the studies which demonstrated the efficacy of monotherapy for relapsed SCLC involved mainly Japanese patients. Therefore, it is necessary to conduct more clinical studies in non-Japanese patients to confirm the efficacy of amrubicin.Keywords: amrubicin, amrubicinol, small cell lung cancer, relapse
Affiliate Program     

Tango Rapperswil
Tango Rapperswil